曲妥珠单抗美坦新(T-DM1)对比医生选择方案治疗经治HER2阳性转移性乳腺癌(TH3RESA):随机开放标签3期试验的最终总生存结果
TH3RESA研究纳入既往接受曲妥珠单抗、拉帕替尼及紫杉类治疗、且晚期阶段至少两种抗HER2方案进展的HER2阳性晚期乳腺癌患者602例,按2:1随机接受曲妥珠单抗美坦新或医生选择方案。最终总生存分析显示曲妥珠单抗美坦新组中位总生存22.7个月,医生选择方案组15.8个月,风险比为0.68,差异有统计学意义。
要点
- 曲妥珠单抗美坦新组中位总生存22.7个月,医生选择方案组15.8个月,风险比0.68
- 曲妥珠单抗美坦新组3级及以上不良事件发生率为40%,医生选择方案组为47%
- 作者认为该结果进一步巩固了曲妥珠单抗美坦新在经治HER2阳性晚期乳腺癌治疗中的地位
核心结论
- 在至少两种抗HER2方案治疗进展的患者中,曲妥珠单抗美坦新治疗较医生选择方案显著改善总生存。
- 作者认为这些数据进一步巩固了曲妥珠单抗美坦新在经治HER2阳性晚期乳腺癌患者管理中的作用,并证实即使经过多线既往治疗,HER2仍是治疗靶点。
研究设计与样本
- TH3RESA为随机、平行分组、开放标签的3期研究。
- 入组患者为年龄≥18岁的男性和女性,中心确认HER2阳性晚期乳腺癌,既往在晚期阶段接受过曲妥珠单抗和拉帕替尼、在任何阶段接受过紫杉类,且在晚期阶段两种或以上抗HER2方案后进展。
- 患者需美国东部肿瘤协作组体能状态评分为0至2分、左心室射血分数至少50%、器官功能良好。
- 2011年9月14日至2012年11月19日,共从22个国家146个中心入组602例患者,随机分配至曲妥珠单抗美坦新组(404例)或医生选择方案组(198例)。
- 按交互式语音和网络应答系统以区组大小为6的置换区组随机化,按2:1随机分配,按世界区域、晚期乳腺癌既往方案数和是否存在内脏疾病分层。
主要发现
- 曲妥珠单抗美坦新组中位总生存为22.7个月(95%CI 19.4-27.5),医生选择方案组为15.8个月(95%CI 13.5-18.7),风险比0.68(95%CI 0.54-0.85),p=0.0007。
- 数据截止2015年2月13日,医生选择方案组198例中93例(47%)已交叉至曲妥珠单抗美坦新组。
- 曲妥珠单抗美坦新组403例中161例(40%)发生3级或以上不良事件,医生选择方案组184例中87例(47%)。
- 医生选择方案组较曲妥珠单抗美坦新组更常见的3级或以上不良事件包括腹泻(3/403例[1%] vs 8/184例[4%])、中性粒细胞减少(10/403例[3%] vs 29/184例[16%])和发热性中性粒细胞减少(1/403例[<1%] vs 7/184例[4%])。
- 曲妥珠单抗美坦新组较医生选择方案组更常见的3级或以上不良事件为血小板减少(24/403例[6%] vs 5/184例[3%])和任何类型出血(17/403例[4%] vs 1/184例[<1%])。
关键数值与推荐
- 曲妥珠单抗美坦新给药方案为3.6 mg/kg静脉给药,每21天一次。
- 研究方案于2012年9月12日修订,允许疾病进展的患者从医生选择方案交叉至曲妥珠单抗美坦新。
- 共同主要终点为意向治疗人群中研究者评估的无进展生存和总生存。
- 本次报告为预先计划的第二次总生存期中分析,计划在预期492例死亡中约67%(n=330)发生时进行。
- 严重不良事件在曲妥珠单抗美坦新组403例中报告102例(25%),医生选择方案组184例中报告41例(22%)。
临床怎么用
- 研究方案本身为曲妥珠单抗美坦新3.6 mg/kg静脉给药每21天一次对比医生选择方案,按当地实践给药,并非作者给出的推荐。
- 作者认为曲妥珠单抗美坦新在经治HER2阳性晚期乳腺癌患者管理中的作用得到进一步巩固。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In the randomised, parallel assignment, open-label, phase 3 TH3RESA study, progression-free survival was significantly longer with trastuzumab emtansine versus treatment of physician's choice in previously treated patients with HER2-positive advanced breast cancer. We report results from the final overall survival analysis of the TH3RESA trial. METHODS: Eligible patients for the TH3RESA trial were men and women (aged ≥18 years) with centrally confirmed HER2-positive advanced breast cancer previously treated with both trastuzumab and lapatinib (advanced setting) and a taxane (any setting) and with progression on two or more HER2-directed regimens in the advanced setting. Patients had to have an Eastern Cooperative Oncology Group performance status of 0-2, left ventricular ejection fraction of at least 50%, and adequate organ function. Patients were randomly assigned (2:1) by an interactive voice and web response system with permuted block randomisation in blocks of six to receive trastuzumab emtansine (3·6 mg/kg intravenously every 21 days) or treatment of physician's choice administered per local practice. Randomisation was stratified by world region, number of previous regimens for advanced breast cancer, and presence of visceral disease. On Sept 12, 2012, the study protocol was amended to allow patients with disease progression to crossover from treatment of physician's choice to trastuzumab emtansine. The coprimary endpoints for TH3RESA were investigator-assessed progression-free survival and overall survival in the intention-to-treat population. We report results from a preplanned second interim analysis of overall survival, which was planned for when approximately 67% (n=330) of 492 expected deaths had occurred. This study is registered with ClinicalTrials.gov, number NCT01419197. FINDINGS: Between Sept 14, 2011, and Nov 19, 2012, 602 patients were enrolled from 146 centres in 22 countries and randomly assigned to trastuzumab emtansine (n=404) or treatment of physician's choice (n=198). At data cutoff (Feb 13, 2015), 93 (47%) of 198 patients in the physician's choice group had crossed over to trastuzumab emtansine. Overall survival was significantly longer with trastuzumab emtansine versus treatment of physician's choice (median 22·7 months [95% CI 19·4-27·5] vs 15·8 months [13·5-18·7]; hazard ratio 0·68 [95% CI 0·54-0·85]; p=0·0007). As the stopping boundary for overall survival was crossed, this overall survival analysis serves as the final and confirmatory analysis of overall survival and the study was terminated according to the protocol. The incidence of grade 3 or worse adverse events was 161 (40%) of 403 patients in the trastuzumab emtansine group and 87 (47%) of 184 patients in the treatment of physician's choice group. Of the most common grade 3 or worse adverse events (affecting ≥2% of patients in either group), those with a 3% or greater difference in incidence between groups that were more frequent with treatment of physician's choice than with trastuzumab emtansine were diarrhoea (three [1%] of 403 patients in the trastuzumab emtansine group vs eight [4%] of 184 patients in the treatment of physician's choice group), neutropenia (ten [3%] vs 29 [16%]), and febrile neutropenia (one [<1%] vs seven [4%]); whereas those that were more frequent with trastuzumab emtansine were thrombocytopenia (24 [6%] of 403 patients vs five [3%] of 184 patients) and haemorrhage of any type (17 [4%] of 403 vs one [<1%] of 184). Serious adverse events were reported in 102 (25%) of 403 patients in the trastuzumab emtansine group and 41 (22%) of 184 in the physician's choice group. Deaths from adverse events were reported in three patients (2%) in the physician's choice group (of which one was judged to be treatment related) and nine (2%) in the trastuzumab emtansine group (of which three were judged to be treatment related). INTERPRETATION: In patients who had progressed on two or more HER2-directed regimens, trastuzumab emtansine treatment resulted in a significant improvement in overall survival versus treatment of physician's choice. These data further solidify the role of trastuzumab emtansine in the management of patients with previously treated HER2-positive advanced breast cancer, and validate HER2 as a therapeutic target even after multiple lines of previous therapy. FUNDING: F Hoffman-La Roche/Genentech.
引用
- Krop IE, Kim SB, Martin AG, et al. Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial. Lancet Oncol. 2017. PMID: 28526538. doi:10.1016/S1470-2045(17)30313-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。